Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus
Sodium glucose cotransporter 2 (SGLT2), a type of membrane protein highly expressed in the kidney, can regulate plasma glucose through the glomerular filtration process by reabsorption from the kidney. SGLT2 inhibitors, which are newly developed oral antidiabetic drugs, can play a role in liver dise...
Main Authors: | Enxiang Zhang, Yang Zhao, Hongbo Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Health/LWW
2021-05-01
|
Series: | Hepatology Communications |
Online Access: | https://doi.org/10.1002/hep4.1611 |
Similar Items
-
Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
by: Alessandro Mantovani, et al.
Published: (2020-12-01) -
Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
by: Ahmadieh H, et al.
Published: (2017-05-01) -
Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy
by: Farah Khaznadar, et al.
Published: (2023-10-01) -
Research progress of sodium-glucose cotransporter 2 inhibitor in non-alcoholic fatty liver disease
by: HUANG Lichenlu, ZHANG Jiarui, ZHENG Yongqin, HE Jundong
Published: (2023-10-01) -
Safety and effectiveness of the sodium‐glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus
by: Michael J. Hadd, et al.
Published: (2023-05-01)